139 related articles for article (PubMed ID: 16835015)
1. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences.
Feldmeyer N; Schmeiser HH; Muehlbauer KR; Belharazem D; Knyazev Y; Nedelko T; Hollstein M
Mutat Res; 2006 Sep; 608(2):163-8. PubMed ID: 16835015
[TBL] [Abstract][Full Text] [Related]
2. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene.
Liu Z; Hergenhahn M; Schmeiser HH; Wogan GN; Hong A; Hollstein M
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):2963-8. PubMed ID: 14976251
[TBL] [Abstract][Full Text] [Related]
3. The carcinogenic air pollutant 3-nitrobenzanthrone induces GC to TA transversion mutations in human p53 sequences.
vom Brocke J; Krais A; Whibley C; Hollstein MC; Schmeiser HH
Mutagenesis; 2009 Jan; 24(1):17-23. PubMed ID: 18765419
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts.
Kucab JE; van Steeg H; Luijten M; Schmeiser HH; White PA; Phillips DH; Arlt VM
Mutat Res; 2015 Mar; 773():48-62. PubMed ID: 25847421
[TBL] [Abstract][Full Text] [Related]
5. The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro.
Sborchia M; De Prez EG; Antoine MH; Bienfait L; Indra R; Valbuena G; Phillips DH; Nortier JL; Stiborová M; Keun HC; Arlt VM
Arch Toxicol; 2019 Nov; 93(11):3345-3366. PubMed ID: 31602497
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors.
Liu Z; Muehlbauer KR; Schmeiser HH; Hergenhahn M; Belharazem D; Hollstein MC
Cancer Res; 2005 Apr; 65(7):2583-7. PubMed ID: 15805253
[TBL] [Abstract][Full Text] [Related]
7. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
8. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.
Arlt VM; Stiborova M; Schmeiser HH
Mutagenesis; 2002 Jul; 17(4):265-77. PubMed ID: 12110620
[TBL] [Abstract][Full Text] [Related]
9. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR.
Arlt VM; Schmeiser HH; Pfeifer GP
Carcinogenesis; 2001 Jan; 22(1):133-40. PubMed ID: 11159751
[TBL] [Abstract][Full Text] [Related]
10. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer.
Arlt VM; Stiborová M; vom Brocke J; Simões ML; Lord GM; Nortier JL; Hollstein M; Phillips DH; Schmeiser HH
Carcinogenesis; 2007 Nov; 28(11):2253-61. PubMed ID: 17434925
[TBL] [Abstract][Full Text] [Related]
11. Mutagenicity of N-hydroxy-4-aminobiphenyl in human TP53 knock-in (Hupki) mouse embryo fibroblasts.
Hölzl-Armstrong L; Kucab JE; Zwart EP; Luijten M; Phillips DH; Arlt VM
Environ Mol Mutagen; 2021 Apr; 62(4):252-264. PubMed ID: 33620775
[TBL] [Abstract][Full Text] [Related]
12. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.
Stiborova M; Frei E; Arlt VM; Schmeiser HH
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):5-11. PubMed ID: 19365519
[TBL] [Abstract][Full Text] [Related]
13. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72.
Reinbold M; Luo JL; Nedelko T; Jerchow B; Murphy ME; Whibley C; Wei Q; Hollstein M
Oncogene; 2008 Apr; 27(19):2788-94. PubMed ID: 17998932
[TBL] [Abstract][Full Text] [Related]
14. p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy.
Slade N; Moll UM; Brdar B; Zorić A; Jelaković B
Mutat Res; 2009 Apr; 663(1-2):1-6. PubMed ID: 19428366
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53.
Simões ML; Hockley SL; Schwerdtle T; Gamboa da Costa G; Schmeiser HH; Phillips DH; Arlt VM
Toxicol Appl Pharmacol; 2008 Oct; 232(1):86-98. PubMed ID: 18639569
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the mutagenicity of aristolochic acid I and aristolochic acid II in the gpt delta transgenic mouse kidney.
Xing G; Qi X; Chen M; Wu Y; Yao J; Gong L; Nohmi T; Luan Y; Ren J
Mutat Res; 2012 Mar; 743(1-2):52-8. PubMed ID: 22245565
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Aristolochic acid I derived DNA adduct levels in human renal toxicity models.
Bastek H; Zubel T; Stemmer K; Mangerich A; Beneke S; Dietrich DR
Toxicology; 2019 May; 420():29-38. PubMed ID: 30940547
[TBL] [Abstract][Full Text] [Related]
18. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy.
Lord GM; Hollstein M; Arlt VM; Roufosse C; Pusey CD; Cook T; Schmeiser HH
Am J Kidney Dis; 2004 Apr; 43(4):e11-7. PubMed ID: 15042566
[TBL] [Abstract][Full Text] [Related]
19. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model.
Kucab JE; Phillips DH; Arlt VM
FEBS J; 2010 Jun; 277(12):2567-83. PubMed ID: 20553493
[TBL] [Abstract][Full Text] [Related]
20. Mutations associated with in vivo aflatoxin B1-induced carcinogenesis need not be present in the in vitro transformations by this toxin.
Stanley LA; Mandel HG; Riley J; Sinha S; Higginson FM; Judah DJ; Neal GE
Cancer Lett; 1999 Apr; 137(2):173-81. PubMed ID: 10374839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
